What's in Chiesi USA, Inc.'s pipeline?

Chiesi USA, Inc. has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Chiesi USA, Inc.'s portfolio?

Top competitors by shared drug class: AbbVie, ONY.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/chiesi-usa-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Chiesi USA, Inc. — Portfolio Competitive Intelligence Brief

Chiesi USA, Inc. pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Curosurf	PORACTANT ALFA	marketed	Surfactant [EPC]		Respiratory	1999-01-01

Therapeutic area mix

Respiratory · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AbbVie · 1 shared drug class
ONY · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Chiesi USA, Inc.:

Cite this brief

Drug Landscape (2026). Chiesi USA, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/chiesi-usa-inc. Accessed 2026-05-16.